Please login to the form below

Not currently logged in
Email:
Password:

buprenorphine

This page shows the latest buprenorphine news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

In a press release, the company says its launch – originally slated for the fourth quarter – will now be reviewed in light of a recent court decision relating to Suboxone (buprenorphine/naloxone) ... Perseris is a key product in Indivior’s

Latest news

  • The year of the blockbuster The year of the blockbuster

    Sublocade (buprenorphine) from Indivior:Sublocade, having been launched in the US in March, could disrupt the market for medication-assisted treatment options to overcome opioid dependence.

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    The US regulator issued a ‘refusal to file’letter to the company yesterday for the drug, which is a fixed-dose combination of buprenorphine, an opioid used for many years to

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    That would help counteract a major setback for the business in the US a few weeks back when it lost a patent infringement lawsuit involving its main product Suboxone (buprenorphine and ... emergency, while FDA Commissioner Scott Gottlieb has announced

  • CHMP backs maintenance therapy for Tesaro's Zejula CHMP backs maintenance therapy for Tesaro's Zejula

    Also given the nod were two drugs from Mundipharma intended to help people with opioid addiction – Nyxoid (naloxone) and Zubsolv (buprenorphine/naloxone), while Spanish drugmaker Grifols got the go-ahead for

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for ... of buprenorphine for treating opioid dependence.

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    deal? Coincidentally, the third late stage deal this month is also an analgesic, a buprenorphine implant lasting for six months for maintenance treatment of opioid dependence; the NDA was submitted in ... 335. Titan / Braeburn. Commercialisation and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics